Stephen Waxman, MD, PhD
Bridget M. Flaherty Professor of Neurology and of NeuroscienceCards
About
Titles
Bridget M. Flaherty Professor of Neurology and of Neuroscience
Director, Center for Neuroscience and Regeneration Research
Biography
Stephen G. Waxman, MD, PhD
Stephen Waxman is the Bridget Flaherty Professor of Neurology, Neuroscience and Pharmacology at Yale University. He served as Chairman of Neurology at Yale from 1986 until 2009. He founded the Neuroscience & Regeneration Research Center at Yale in 1988 and is its Director. Prior to Yale, he held faculty positions at Harvard, MIT, and Stanford.
Dr. Waxman’s research capitalizes on the “molecular revolution” to develop new therapies that can restore function after nervous system injury. He has published more than 800 scientific papers. His H-index is 126 and his papers have been cited more than 60,000 times.
Dr. Waxman’s first paper in Nature was published in 1970. His research defined the ion channel architecture of nerve fibers, and demonstrated its importance for axonal conduction (Science, 1985). He demonstrated sodium channel plasticity that supports recovery of impulse conduction in demyelinated axons (Science, 1982), and pinpointed the molecular identity of the channels that restore impulse conduction in MS (PNAS, 2004), His molecule-to-man studies on pain include a translational leap from laboratory to humans, where he used molecular genetics, molecular biology, and biophysics to demonstrate the role of ion channels in human pain (PNAS, 2006). He led an international coalition that identified sodium channel mutations as causes of peripheral neuropathy (PNAS, 2012). He has used atomic-level modeling to advance pharmacogenomics in a paper (JAMA Neurology, 2016), accompanied by an editorial stating “there are few examples in clinical medicine where molecular reasoning has been rewarded with comparable success”. A new class of non-addictive pain medications, based largely on his work, is currently in Phase II clinical trials. He is now pinpointing “pain resilience” genes, and has identified an ion channel that controls joint degeneration in osteoarthritis (Nature, 2024).
Waxman has authored Spinal Cord Compression and Clinical Neuroanatomy (translated into 8 languages). He has served on multiple editorial boards including Annals of Neurology, Brain, Journal of Physiology, Trends in Molecular Medicine, and Nature Reviews Neurology. He is the Editor of The Neuroscientist. His trainees lead research teams around the world.
Dr. Waxman is a member of the National Academy of Medicine, and has served on the Board of Scientific Counselors of NINDS. His honors include the Dystel Prize and Wartenberg Award (Amer. Acad. of Neurology), the Middleton Award and Magnuson Award (Veterans Admin/), and the Soriano Award (Amer. Neurol. Assn). He was honored with the British Physiological Society’s Annual Prize, an accolade he shares with his heroes Nobel Prize laureates Andrew Huxley, John Eccles, and Alan Hodgkin. Most recently, Waxman received the Julius Axelrod Prize (Soc. for Neuroscience), and the Mitchell Max Award (Amer. Acad. of Neurology)
Appointments
Neurology
ProfessorPrimaryNeuroscience
ProfessorSecondaryPharmacology
ProfessorSecondary
Other Departments & Organizations
Education & Training
- Resident
- Boston City Hospital (1975)
- Clinical Fellow
- Harvard Medical School (1975)
- Postdoctoral Fellow
- MIT (1975)
- MD
- Albert Einstein College of Medicine (1972)
- PhD
- Albert Einstein College of Medicine (1970)
Board Certifications
Neurology
- Certification Organization
- AB of Psychiatry & Neurology
- Original Certification Date
- 1977
Research
Overview
My laboratory focuses on functional recovery in diseases of the brain and spinal cord. In particular, we use a spectrum of methods including molecular biology and genetics, cell biology, electrophysiology, computer simulations, molecular modeling etc. to understand how the nervous system responds to injury, and how we can induce functional recovery. Approaching these issues from a molecule- and mechanism-driven standpoint, we have a special interest in spinal cord injury, multiple sclerosis, and neuropathic pain. Our early studies demonstrated the molecular basis for remissions in MS. We have a major interest in the role of ion channels in diseases of the brain and spinal cord. We have demonstrated, for example, that following injury to their axons, spinal sensory neurons turn off some sodium channel genes, while turning others on. This results in the production of different types of sodium channels (with different kinetics and voltage-dependencies) in these neurons, causing them to become hyperexcitability and thereby contributing to neuropathic pain.
We are also interested in hereditary neuropathic pain and have delineated, for the first time, the molecular basis for a hereditary pain syndrome (inherited erythromelalgia; OMIM #133020;#603415). We have identified mutations in ion channel genes that cause painful peripheral neuropathy, and are moving toward pharmacogenomically-guided pain pharmacotherapy. We have also used molecular genetics and stem-cell derived models to identify pain resilience genes.
We are using state-of-the art molecular imaging to determine how nerve cell build their excitable membranes, molecule by molecule. My laboratory is also examining the role of abnormal sodium channel expression in spinal cord injury (SCI) and multiple sclerosis (MS). Specific projects focus on molecular mechanisms of recovery of conduction along demyelinated axons, and on molecular substrates of axonal degeneration. We are also studying neuroprotection, and have demonstrated that it is possible to pharmacologically protect axons, so they don't degenerate in SCI and MS.
Medical Subject Headings (MeSH)
Academic Achievements & Community Involvement
News
News
- November 07, 2024
Peripheral Sodium Channel Blocker Could Revolutionize Treatment for Nerve Pain
- January 03, 2024
Breakthrough in Osteoarthritis Research: Nav1.7 Sodium Channels Unveiled as Potential Game-Changer
- January 03, 2024Source: YaleNews
Epilepsy Drug Shows Promise in Slowing Joint Degeneration in Osteoarthritis
- August 03, 2023
Clinical Trial Builds Upon Yale Studies to Provide Proof-of-Concept that Subtype-specific Sodium Channel Blockers can Reduce Pain in Humans